Mar 2, 2026 06:43AM
Mar 1, 2026 12:30PM
Mar 1, 2026 12:30PM
Feb 27, 2026 06:54AM
Feb 26, 2026 07:00AM
Feb 17, 2026 08:00AM
Feb 5, 2026 08:00AM Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
Jan 9, 2026 08:02AM
Jan 9, 2026 08:00AM
Dec 12, 2025 04:55AM
Dec 11, 2025 07:30AM
Dec 11, 2025 07:30AM
Dec 10, 2025 04:01PM
Dec 10, 2025 04:01PM Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
Nov 10, 2025 07:00AM
Nov 7, 2025 07:30AM
Nov 7, 2025 07:30AM
Nov 5, 2025 04:02PM
Nov 5, 2025 04:01PM
Nov 4, 2025 07:00AM
Oct 21, 2025 04:01PM Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Aug 27, 2025 04:01PM
Aug 21, 2025 04:09AM
Aug 20, 2025 04:01PM
Aug 20, 2025 04:01PM
Aug 5, 2025 07:00AM
Jul 22, 2025 04:01PM
Jul 12, 2025 06:00PM Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
Jul 9, 2025 08:00AM
Jul 9, 2025 08:00AM
Jul 8, 2025 04:03PM
Jul 8, 2025 04:01PM
Jun 26, 2025 04:08AM
Jun 25, 2025 08:00AM
May 14, 2025 08:03AM Rhythm Pharmaceuticals (RYTM) Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months
May 14, 2025 08:00AM
May 7, 2025 07:00AM
May 6, 2025 08:00AM
Apr 23, 2025 08:00AM
Apr 7, 2025 12:16PM
Apr 7, 2025 07:00AM
Apr 7, 2025 07:00AM Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
Apr 6, 2025 12:00PM
Mar 20, 2025 04:09PM
Mar 20, 2025 04:01PM
Mar 19, 2025 04:01PM
Mar 19, 2025 04:01PM
Feb 26, 2025 07:00AM
Feb 13, 2025 08:00AM Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025
Feb 5, 2025 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All